MCID: INF009
MIFTS: 32

Inflammatory Spondylopathy

Categories: Bone diseases

Aliases & Classifications for Inflammatory Spondylopathy

MalaCards integrated aliases for Inflammatory Spondylopathy:

Name: Inflammatory Spondylopathy 12 15
Inflammatory Spondylopathies in Disease Classified Elsewhere 12
Inflammatory Spondylopathy in Disease Classified Elsewhere 12
Inflammatory Spondylopathies in Disease Ec 12
Spondylitis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12105
ICD9CM 34 720.81
SNOMED-CT 67 6963001
ICD10 32 M46.8 M46.9
UMLS 71 C0021396 C0038012

Summaries for Inflammatory Spondylopathy

MalaCards based summary : Inflammatory Spondylopathy, also known as inflammatory spondylopathies in disease classified elsewhere, is related to discitis and spondylitis, and has symptoms including sciatica An important gene associated with Inflammatory Spondylopathy is LINC00523 (Long Intergenic Non-Protein Coding RNA 523). The drugs Esomeprazole and Loxoprofen have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes.

Related Diseases for Inflammatory Spondylopathy

Diseases related to Inflammatory Spondylopathy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 discitis 10.4
2 spondylitis 10.4

Symptoms & Phenotypes for Inflammatory Spondylopathy

UMLS symptoms related to Inflammatory Spondylopathy:


sciatica

Drugs & Therapeutics for Inflammatory Spondylopathy

Drugs for Inflammatory Spondylopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
2
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
3
Aceclofenac Approved, Investigational Phase 4 89796-99-6
4
Pamidronate Approved Phase 4 40391-99-9 4674
5
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
7
carbamide peroxide Approved Phase 4 124-43-6
8
Tofacitinib Approved, Investigational Phase 4 477600-75-2
9
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
10
Hydroxychloroquine Approved Phase 4 118-42-3 3652
11
Etanercept Approved, Investigational Phase 4 185243-69-0
12
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15 Anti-Infective Agents Phase 4
16 Proton Pump Inhibitors Phase 4
17 Anti-Ulcer Agents Phase 4
18 Antacids Phase 4
19 Natriuretic Agents Phase 4
20 Natriuretic Peptide, Brain Phase 4
21 Tripterygium Phase 4
22 Endothelial Growth Factors Phase 4
23 Mitogens Phase 4
24 Cholestyramine Resin Phase 4
25 Tocolytic Agents Phase 4
26 Cyclooxygenase 2 Inhibitors Phase 4
27 Protein Kinase Inhibitors Phase 4
28 Antibodies, Monoclonal Phase 4
29 Antibodies Phase 4
30 Immunoglobulins Phase 4
31 Antiparasitic Agents Phase 4
32 Antimalarials Phase 4
33 Antiprotozoal Agents Phase 4
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Analgesics, Non-Narcotic Phase 4
36 Analgesics Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Antipyretics Phase 4
39 Narcotics Phase 4
40 Analgesics, Opioid Phase 4
41 Central Nervous System Depressants Phase 4
42
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
44
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
45
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
46 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
47
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
48
Certolizumab pegol Approved Phase 3 428863-50-7
49
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
50
Misoprostol Approved Phase 3 59122-46-2 5282381

Interventional clinical trials:

(show top 50) (show all 414)
# Name Status NCT ID Phase Drugs
1 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
6 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
7 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
10 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
11 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
12 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
13 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
14 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
15 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
16 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
17 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
18 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
19 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
20 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
21 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
22 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
23 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
24 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
25 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
26 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
27 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
28 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
31 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
32 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
33 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
34 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
35 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
36 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
37 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
38 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
39 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
40 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
41 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
42 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
43 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
44 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
45 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
46 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Recruiting NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
47 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
48 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
49 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
50 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)

Search NIH Clinical Center for Inflammatory Spondylopathy

Genetic Tests for Inflammatory Spondylopathy

Anatomical Context for Inflammatory Spondylopathy

MalaCards organs/tissues related to Inflammatory Spondylopathy:

40
Bone, T Cells, Testes, Spinal Cord, Lung, Endothelial, Heart

Publications for Inflammatory Spondylopathy

Articles related to Inflammatory Spondylopathy:

(show top 50) (show all 16236)
# Title Authors PMID Year
1
Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. 61
31848735 2020
2
Comment on "Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis". 61
31955227 2020
3
Reply to: Comment on "effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis" by Cure et al. 61
32002652 2020
4
The coexistence of gout in ankylosing spondylitis patients: a case control study. 61
31630236 2020
5
A positive Helicobacter pylori test is associated with low spondylarthritis incidence in a Danish historical cohort study. 61
31802207 2020
6
Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. 61
31848736 2020
7
Real-time PCR based HLA-B*27 screening directly in whole blood. 61
31749313 2020
8
New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. 61
32034553 2020
9
Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study. 61
32029494 2020
10
Multimorbidity in Axial Spondyloarthropathy and Its Association with Disease Outcomes: Results from the Ankylosing Spondylitis Registry of Ireland Cohort. 61
31092715 2020
11
Systemic changes associated with quality of life after surgical treatment of kyphotic deformity in patients with ankylosing spondylitis: a systematic review. 61
32020389 2020
12
Impact of cervical range of motion on the global spinal alignment in ankylosing spondylitis patients with thoracolumbar kyphosis following pedicle subtraction osteotomy. 61
31525472 2020
13
Prediction of Ankylosing Spondylitis in the HUNT Study by a Genetic Risk Score Combining 110 Single-nucleotide Polymorphisms of Genome-wide Significance. 61
30936278 2020
14
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. 61
31736377 2020
15
Associations of the IL-1B level, IL-1A and IL-1B gene polymorphisms and ankylosing spondylitis risk in a Chinese Han population. 61
31726259 2020
16
Neuromyelitis optica spectrum disorder coexisting with ankylosing spondylitis: A case report. 61
32036261 2020
17
Ankylosing Spondylitis Physical Performance Index (ASPI): objective test for physical functioning is highly reliable and feasible. 61
32007935 2020
18
Discovery of Potential Serum Protein Biomarkers in Ankylosing Spondylitis Using Tandem Mass Tag-Based Quantitative Proteomics. 61
31917576 2020
19
Pseudoseptic arthritis of the hip as the initial presentation of ankylosing spondylitis. 61
32037710 2020
20
Associations of lumbar scoliosis with presentation of suspected early axial spondyloarthritis. 61
31277929 2020
21
Validity and reliability of Work Productivity and Activity Impairment among patients with axial spondyloarthritis in Singapore. 61
32020752 2020
22
Lymphoprolipherative skin reactions induced by anti-TNFα: an open question. 61
30724650 2020
23
Molecular mechanisms and clinical application of Iguratimod: A review. 61
31918275 2020
24
High accuracy of HLA-B*27 genotyping by allele-specific real-time polymerase chain reaction in a heterogeneous population compared to flow cytometry and single nucleotide polymorphism detection assays. 61
31902620 2020
25
The Epidemiology and Clinical Manifestations of Autoimmunity in Selective IgA Deficiency. 61
31267472 2020
26
Similarities between pediatric FMF patients with sacroiliitis and pediatric juvenile spondyloarthropathy patients with sacroiliitis: a preliminary study. 61
32009575 2020
27
Expert consensus on a set of outcomes to assess the effectiveness of biologic treatment in psoriatic arthritis: the MERECES study. 61
32007930 2020
28
Notoginsenoside R1 suppresses miR-301a via NF-κB pathway in lipopolysaccharide-treated ATDC5 cells. 61
31837326 2020
29
The safety of ixekizumab in psoriasis drug therapy. 61
31874129 2020
30
Epidemiology of uveitis in a region of southern Sweden. 61
31161663 2020
31
Effect of Interleukin-34 on Secretion of Angiogenesis Cytokines by Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis. 61
31401905 2020
32
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. 61
31206593 2020
33
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. 61
31852268 2020
34
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. 61
32014044 2020
35
Psoriasis is an independent risk factor for entheseal damage in axial spondyloarthritis. 61
31324469 2020
36
Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. 61
31773391 2020
37
Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). 61
31662321 2020
38
Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden. 61
32020767 2020
39
Crowned dens syndrome, yet another rheumatic disease imposter. 61
31713735 2020
40
Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). 61
31791950 2020
41
Prevalence of axial spondyloarthritis in Poland. 61
31802208 2020
42
Assessment of Ocular Surface in Patients With Ankylosing Spondylitis. 61
30817331 2020
43
Changes in the medical burden of pyogenic and tuberculous spondylitis between 2007 and 2016: A nationwide cohort study. 61
31952970 2020
44
Neurological recovery after early decompression for dorsal Pott's spine. 61
31874383 2020
45
Cognitive impairment in patients with ankylosing spondylitis. 61
31928545 2020
46
The efficacy and safety of Health Qigong for ankylosing spondylitis: Protocol for a systematic review and meta-analysis. 61
32011452 2020
47
Aberrant distribution and function of plasmacytoid dendritic cells in patients with ankylosing spondylitis are associated with unfolded protein response. 61
31961055 2020
48
Inter-segmental coordination of the spine is altered during lifting in patients with ankylosing spondylitis: A cross-sectional study. 61
32000413 2020
49
Identification of RELN variant p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis; the first association of RELN and AS. 61
32001840 2020
50
Combined percutaneous and open instrumentation for thoracolumbar kyphosis correction by two-level pedicle subtraction osteotomy in ankylosing spondylitis. 61
31980911 2020

Variations for Inflammatory Spondylopathy

Expression for Inflammatory Spondylopathy

Search GEO for disease gene expression data for Inflammatory Spondylopathy.

Pathways for Inflammatory Spondylopathy

GO Terms for Inflammatory Spondylopathy

Sources for Inflammatory Spondylopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....